Zobrazeno 1 - 10
of 90
pro vyhledávání: '"CYRUS KHAN"'
Autor:
Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquín Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppa, Pauline Baumlin, Linda Lundberg, James Relf, Yuying Xie, Alessia Bottos, Kathryn Humphrey, Lorenzo Falchi
Publikováno v:
HemaSphere, Vol 7, p e458981a (2023)
Externí odkaz:
https://doaj.org/article/c4495cc7d2714f60818218c0cb6a1f50
Publikováno v:
Frontiers in Systems Neuroscience, Vol 8 (2015)
Interruptions to ongoing mental activities are omnipresent in our modern digital world, but the brain networks involved in interrupted performance are not known, nor have the activation of those networks been modulated. Errors following interruptions
Externí odkaz:
https://doaj.org/article/6487d541765f47968e2c5a13acf814a7
Autor:
Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Jeff P. Sharman
Publikováno v:
Blood Advances. 7:1488-1495
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in ∼60% of patients. Atezolizumab is a humanized immunoglobul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc1b97a21d171847f261eab8a339b3c
https://doi.org/10.1182/bloodadvances.2022008344
https://doi.org/10.1182/bloodadvances.2022008344
Publikováno v:
Journal of Hematology. 12:87-91
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0defce1f5525bb00b6d496d1f5cdeb31
https://doi.org/10.14740/jh1113
https://doi.org/10.14740/jh1113
Autor:
Muath, Abdeen, Urwat Til, Vusqa, Palash, Asawa, Kiley, Felton, Derek, Rinchuse, Cyrus, Khan, Yazan, Samhouri, John, Lister
Publikováno v:
Anti-Cancer Drugs. 33:1167-1170
Venetoclax, a highly selective Bcl-2 inhibitor, is an orally bioavailable drug that has been approved as first-line therapy for chronic lymphocytic leukemia (CLL) in combination with obinutuzumab, as well as monotherapy in the setting of relapsed CLL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0692fad4c51f2b8314fc09fde75108cf
https://doi.org/10.1097/cad.0000000000001350
https://doi.org/10.1097/cad.0000000000001350
Autor:
Moaath K. Mustafa Ali, Yazan Samhouri, Jennie Y. Law, Cyrus Khan, Rodney Wegner, Seung Tae Lee, John Lister
Publikováno v:
Breast Cancer. 29:1022-1031
Primary breast lymphoma (PBL) is managed differently among centers, using surgery, systemic therapy and/or radiation. With data derived from the National Cancer Database (NCDB), we aim to describe treatments utilized in the United States, estimate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::410d5ebc7876c8f9bcb25d28b5a7aff0
https://doi.org/10.1007/s12282-022-01382-w
https://doi.org/10.1007/s12282-022-01382-w
Autor:
Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Krish Patel, Mark Hertzberg, Lorenzo Falchi, Nancy L. Bartlett, Joshua Brody, Linda Lundberg, Yuying Xie, Estefania Mulvihill, Pauline Baumlin, James Relf, Emily Piccione, Kathryn Humphrey, Michael Dickinson
Publikováno v:
Blood. 140:1062-1064
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0967793d1469a33ff7eac3cec417697
https://doi.org/10.1182/blood-2022-157554
https://doi.org/10.1182/blood-2022-157554
Autor:
Yazan, Samhouri, Moaath K, Mustafa Ali, Cyrus, Khan, Rodney, Wegner, Seung Tae, Lee, John, Lister
Publikováno v:
Anticancer Research. 42:1867-1877
The addition of radiation to chemotherapy in elderly patients with primary central nervous system lymphoma (PCNSL) remains controversial. This aim of this study was to assess the trend of combined modality treatment (CMT) and compare its survival wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a0c0c745e390383c76532745626363
https://doi.org/10.21873/anticanres.15663
https://doi.org/10.21873/anticanres.15663
Autor:
Stefan Knop, Monika Szarejko, Norbert Grząśko, Sara Bringhen, Karolin Trautmann‐Grill, Artur Jurczyszyn, Angelo Vacca, Cyrus Khandanpour, Barbara Gamberi, Ludek Pour, Katrine F. Iversen, Michael T. Stumpp, Cosima Suter, Keith M. Dawson, Christof Zitt, Philippe Legenne, Vaia Stavropoulou, Martin F. Fey, Nicolas Leupin, Hartmut Goldschmidt
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 940-950 (2024)
Abstract MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular endothelial growth factor A (VEGF‐A) and hepatocyte growth factor (HGF), aiming at potentiating cancer therapy by disrupting the tumour microenvironment.
Externí odkaz:
https://doaj.org/article/d9320941c5f7443ea0d680430869e3d7
Primary CNS lymphoma (PCNSL) is an aggressive form of extranodal non-Hodgkin lymphoma that arises in the brain parenchyma, eyes, meninges, or spinal cord in the absence of systemic disease. Primary dural lymphoma (PDL) arises from the dura mater of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::185279a12416a1629447cf7463ec4093
https://doi.org/10.21203/rs.3.rs-2610064/v1
https://doi.org/10.21203/rs.3.rs-2610064/v1
